Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P250003/S001

Embrace(TM) Hydrogel Embolic System

Instylla, Inc. · Decision date Nov 25, 2025

FDA DECISIONP250003/S001

What did the FDA approve?

FDA records P250003/S001 as a supplement to PMA P250003, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Nov 25, 2025.

FDA approval order statement

approval to implement a minimum packaging configuration of 2 shelf boxes/shipper
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
Nov 25, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P250003/S001
Regulatory pathway
PMA supplement
Product code
QVG
Decision code
APPR
Decision date
Nov 25, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Embolization Agent, Vascular.

Product code
QVG
FDA device class
3

For the original device and its historical approval scope, see PMA P250003. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P250003 · Original PMA

    Embrace(TM) Hydrogel Embolic System

  2. P250003/S001 received

    Application receipt date recorded by FDA.

  3. P250003/S001 · FDA decision

    Real-Time Process

  4. P250003/S002 · Related supplement

    Embrace Hydrogel Embolic System (HES)

  5. P250003/S003 · Related supplement

    Embrace Hydrogel Embolic System

  6. P250003/S004 · Related supplement

    Embrace Hydrogel Embolic System (HES)

  7. P250003/S006 · Related supplement

    Embrace Hydrogel Embolic System (HES)

  8. P250003/S005 · Related supplement

    Embrace Hydrogel Embolic System (HES)

  9. P250003/S009 · Related supplement

    Embrace Hydrogel Embolic System

  10. P250003/S010 · Related supplement

    Embrace(TM) Hydrogel Embolic System

  11. P250003/S008 · Related supplement

    Embrace(TM) Hydrogel Embolic System

  12. P250003/S011 · Related supplement

    Embrace Hydrogel Embolic System

Timeline entries are records held by MedtechLedger for P250003. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250003

Product / regulatory recordCompanyPathwayDecision dateSource
Instylla, Inc.PMA approvalAug 5, 2025FDA
Instylla, Inc.PMA supplementDec 17, 2025FDA
Instylla, Inc.PMA supplementFeb 4, 2026FDA
Instylla, Inc.PMA supplementFeb 12, 2026FDA
Instylla, Inc.PMA supplementApr 1, 2026FDA
Instylla, Inc.PMA supplementApr 2, 2026FDA
Instylla, Inc.PMA supplementSep 3, 2026FDA
Instylla, Inc.PMA supplementOct 21, 2026FDA
Instylla, Inc.PMA supplementOct 23, 2026FDA
Instylla, Inc.PMA supplementOct 23, 2026FDA

Explore the linked device profile

Other records with product code QVG

Product / regulatory recordCompanyPathwayDecision dateSource
Sirtex Medical, Inc.PMA supplementJul 9, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Instylla, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
201 Burlington Rd., North Bldg., Bedford, MA, 01730

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records